TriangleTafasitamab (NCT07225439)
Tafasitamab trial for Non Hodgkin Lymphoma (NCT07225439). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
B-cell lymphoma is treatable, often curable, until it comes back. Then engineered CAR T cells changed everything. But they are built from each patient's own cells, take weeks, and fail in nearly half of those who get them.
The idea: an immune cell you can take off the shelf, and two antibodies to aim it.
Natural killer cells from a healthy donor are grown and infused weekly for three weeks. Alongside them, rituximab and tafasitamab coat the lymphoma cells, each grabbing a different surface marker. Coated cells are exactly what natural killer cells are built to destroy.
This trial, in Cleveland with Paolo Caimi and George Deng, is the first test of the combination, asking what dose is safe. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.